Neonc Technologies Holdings, Inc. (NTHI) Stock Score, Valuation & Financial Research

Neonc Technologies Holdings, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NTHI

Neonc Technologies Holdings, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.53. These figures are a research snapshot, not a buy or sell recommendation.

What Neonc Technologies Holdings, Inc. does

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

NeOnc Technologies Holdings, Inc. is a clinical-stage biotechnology company that focuses on the development of novel molecular technologies for treating central nervous system diseases, including brain cancer. The company currently operates in a research and development phase, focusing on advancing its proprietary drug candidates through clinical trials rather than generating commercial revenue from product sales.

Products and services

  • The company's primary product candidates are NEO100, a purified form of perillyl alcohol, and NEO212, a dual-action molecule combining perillyl alcohol and temozolomide, both designed for the treatment of brain tumors.

Brands and product families

  • NEO100 — Lead product candidate for brain tumor treatment. Source
  • NEO212 — Dual-action molecule product candidate. Source

Customer types

Healthcare providers and medical institutions.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct and manage its clinical trials. Source

Business relationships and partnerships

  • NuroMENA — A UAE-based subsidiary focused on advancing regional partnerships and strengthening Abu Dhabi–US collaboration in brain cancer treatment. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company competes with various entities developing therapies for central nervous system diseases and oncology, as disclosed in the risk factors regarding market competition. Source

Business strengths to evaluate

  • Proprietary molecular technology platform for targeted delivery to the central nervous system Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Dependence on successful clinical trial outcomes and regulatory approval Source
  • Need for additional capital to fund research and development activities Source

Sources: Company research source · NuroMENA

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NTHI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.53
Market capitalization:
65.61M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -47.2M
Free cash flow:
USD -20.86M
Cash:
USD 1.97M
Total debt:
USD 328.22K
EPS:
USD -2.22

What stands out

  • Reported year-over-year revenue growth is -100.0%.
  • Free cash flow is USD -20.86M, negative for the stored period.
  • The balance sheet shows USD 1.97M of cash versus USD 328.22K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 1.65M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NTHI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving NTHI's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can NTHI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is NTHI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for NTHI to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of NTHI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research NTHI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.